Bristol-Myers Squibb Co. (BMY) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where th...
Bristol-Myers Squibb Co. (BMY) currently trades at a P/E ratio of 18.69 (historical range: 14.37–23.03, median: 18.11), placing it at the 67th percentile — above its historical average, P/S ratio of 2.80 (range: 1.81–2.86, 99th percentile — expensive relative to its history), EV/EBITDA of 52.44 (range: 11.67–54.78, 98th percentile).
Bristol-Myers Squibb Co. appears overvalued relative to its own historical valuation range, trading at elevated multiples across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 18.69 | 14.37 | 18.11 | 23.03 | 67th | above its historical average |
| P/S Ratio | 2.80 | 1.81 | 2.34 | 2.86 | 99th | expensive relative to its history |
| EV/EBITDA | 52.44 | 11.67 | 26.98 | 54.78 | 98th | expensive relative to its history |
| FCF Yield | 0.01 | 0.01 | 0.06 | 0.13 | 1th | expensive relative to its history |